BlossomHill Therapeutics, Inc. Common Stock (BLSM) — Net Asset Quality Index
BlossomHill Therapeutics, Inc. Common Stock (BLSM) has a Net Asset Quality Index of -106.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $143.41 Million minus total liabilities of $295.53 Million yields net assets of $-152.12 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of BlossomHill Therapeutics, Inc. Common St for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
BlossomHill Therapeutics, Inc. Common Stock Net Asset Quality Index Over Time (2024–2025)
This chart shows how BlossomHill Therapeutics, Inc. Common Stock's Net Asset Quality Index has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the index stands at -106.1%, representing net assets of $-152.12 Million against total assets of $143.41 Million USD. For live market cap and overall valuation, see BLSM market cap.
Annual Net Asset Quality Index for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Net Asset Quality Index for BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See shareholders equity of BlossomHill Therapeutics, Inc. Common St for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -80.8% | $-131.73 Million | $162.97 Million | $294.70 Million | ▼ -12.6 pp |
| 2024 | -68.3% | $-72.88 Million | $106.78 Million | $179.66 Million | — |